Suzhou Basecare Medical Future Growth
Future criteria checks 1/6
Suzhou Basecare Medical is forecast to grow earnings and revenue by 46.5% and 17.3% per annum respectively. EPS is expected to grow by 46.1% per annum. Return on equity is forecast to be -8.1% in 3 years.
Key information
46.5%
Earnings growth rate
46.1%
EPS growth rate
| Medical Equipment earnings growth | 39.9% |
| Revenue growth rate | 17.3% |
| Future return on equity | -8.1% |
| Analyst coverage | Low |
| Last updated | 02 Jul 2024 |
Recent future growth updates
Recent updates
Suzhou Basecare Medical (HKG:2170) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 18
Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) Low P/S
Sep 27Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet
May 30Suzhou Basecare Medical Corporation Limited's (HKG:2170) Shares Leap 27% Yet They're Still Not Telling The Full Story
May 09Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch
Mar 22Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?
Aug 01Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop
May 26Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?
Jul 20Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 374 | -62 | -55 | -25 | 1 |
| 12/31/2025 | 318 | -117 | -137 | -117 | 1 |
| 12/31/2024 | 262 | -160 | -199 | -189 | 1 |
| 6/30/2024 | 247 | -250 | -375 | -266 | N/A |
| 3/31/2024 | 228 | -221 | -373 | -267 | N/A |
| 12/31/2023 | 208 | -192 | -371 | -267 | N/A |
| 9/30/2023 | 183 | -176 | N/A | N/A | N/A |
| 6/30/2023 | 158 | -160 | -331 | -220 | N/A |
| 3/31/2023 | 149 | -146 | -324 | -205 | N/A |
| 12/31/2022 | 141 | -132 | -317 | -189 | N/A |
| 9/30/2022 | 133 | -133 | N/A | N/A | N/A |
| 6/30/2022 | 126 | -135 | -310 | -219 | N/A |
| 3/31/2022 | 117 | -139 | -268 | -208 | N/A |
| 12/31/2021 | 107 | -144 | -227 | -198 | N/A |
| 9/30/2021 | 103 | -119 | -172 | -151 | N/A |
| 6/30/2021 | 99 | -106 | -119 | -107 | N/A |
| 3/31/2021 | 90 | -490 | -96 | -86 | N/A |
| 12/31/2020 | 81 | -874 | -72 | -64 | N/A |
| 9/30/2020 | 71 | -1,008 | -56 | -51 | N/A |
| 6/30/2020 | 61 | -1,116 | -62 | -58 | N/A |
| 3/31/2020 | 58 | -822 | -51 | -48 | N/A |
| 12/31/2019 | 56 | -528 | -41 | -38 | N/A |
| 12/31/2018 | 33 | -152 | -31 | -27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2170 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2170 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2170 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2170's revenue (17.3% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 2170's revenue (17.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2170 is forecast to be unprofitable in 3 years.